Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Lindberg

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
Journal of the American College of Cardiology|November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)John G F Cleland, John J V McMurray, John Kjekshus, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Acta Dermato-Venereologica|April 6, 2023
Establishment and Utility of SwedAD: A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic PharmacotherapyMikael Alsterholm, Axel Svedbom, Chris D Anderson, et al.
Contact Dermatitis|July 17, 2015
European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practiceJeanne D Johansen, Kristiina Aalto-Korte, Tove Agner, et al.
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
Journal of the American College of Cardiology|November 7, 2009
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)John G F Cleland, John J V McMurray, John Kjekshus, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Acta Dermato-Venereologica|April 6, 2023
Establishment and Utility of SwedAD: A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic PharmacotherapyMikael Alsterholm, Axel Svedbom, Chris D Anderson, et al.
Contact Dermatitis|July 17, 2015
European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practiceJeanne D Johansen, Kristiina Aalto-Korte, Tove Agner, et al.
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 13